Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 14/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 13/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 2/20 | 0.43 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3844460 | 0.99 | CYP2D6 (0.45) | L3MBTL3L3MBTL1CYP2D6CYP2C19NPSR1 | |
| Hydrochloric Acid SCHEMBL3845140 | 0.87 | LMNA (0.48) | L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3846474 | 0.85 | LMNA (0.50) | L3MBTL1NPSR1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3844296 | 0.85 | LMNA (0.50) | L3MBTL1NPSR1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3850497 | 0.85 | LMNA (0.50) | L3MBTL1NPSR1MEN1KMT2AALDH1A1 | |
| SCHEMBL12380451 | 0.85 | LMNA (0.49) | L3MBTL1ALDH1A1 | |
| Bromide SCHEMBL15258666 | 0.84 | LMNA (0.51) | L3MBTL1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL3849258 | 0.81 | LMNA (0.46) | L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3847307 | 0.78 | HPGD (0.38) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL4114934 | 0.78 | FKBP1A (0.42) | L3MBTL1CYP2C19MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2085086-A2 | Method for treating congestive heart failure or diabetic nephropathy | Synvista Therapeutics, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| US-20090124674-A1 | Method for treating congestive heart failure | SYNVISTA THERAPEUTICS, INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124673-A1 | Method for treating diabetic nephropathy | SYNVISTA THERAPEUTICS , INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-7432254-B2 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | SYNVISTA THERAPEUTICS, INC. | 2007-02-22 | — | — | US | disclosed |
| US-7166625-B2 | Method for treating fibrotic diseases and other indications | ALTEON, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1353669-A4 | METHOD FOR TREATING GLAUCOMA IB | ALTEON INC (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | SYNVISTA THERAPEUTICS, INC. | 2004-11-25 | — | — | US | disclosed |
| EP-1353669-A1 | METHOD FOR TREATING GLAUCOMA IB | Alteon, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | ALTEON, INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | SYNVISTA THERAPEUTICS, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020160993-A1 | Method for treating glaucoma IC | SYNVISTA THERAPEUTICS, INC. | 2002-10-31 | — | — | US | disclosed |
| WO-2002053158-A1 | METHOD FOR TREATING GLAUCOMA IB | ALTEON, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | ALTEON, INC. | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235837-A1 | Method for treating fibrotic diseases or other indications IE | MMP1, COL1A1, COL2A1 | ACHE 1566/4885L3MBTL3 4327/4885L3MBTL1 3390/4885 |
| US-20020160993-A1 | Method for treating glaucoma IC | CHAT, MYOC, GAP43 | ACHE 32/4885L3MBTL3 4734/4885L3MBTL1 4609/4885 |
| US-20020068729-A1 | Method for treating fibrotic diseases or other indications IC | MMP1, COL1A1, COL2A1 | ACHE 1413/4885L3MBTL3 4309/4885L3MBTL1 3653/4885 |
| US-20030176426-A1 | Method for treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, COL2A1 | ACHE 2654/4885L3MBTL3 2064/4885L3MBTL1 728/4885 |
| US-20090124673-A1 | Method for treating diabetic nephropathy | REN, SLC5A2, SLC5A1 | ACHE 1116/4885L3MBTL3 4370/4885L3MBTL1 4461/4885 |
| US-20020177586-A1 | Method for treating fibrotic diseases or other indications ID | MMP1, COL1A1, COL2A1 | ACHE 1945/4885L3MBTL3 4083/4885L3MBTL1 3021/4885 |
| US-20070043016-A1 | Method of treating fibrotic diseases or other indications with imidazolium agents | MMP1, COL1A1, EPX | ACHE 2361/4885L3MBTL3 1472/4885L3MBTL1 1060/4885 |
| US-20090124674-A1 | Method for treating congestive heart failure | TNNI3, TNNT2, FABP3 | ACHE 657/4885L3MBTL3 2118/4885L3MBTL1 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.